Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.57 |
| ▸ | YARS1 | P54577 | 2/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9822736 | 1.00 | SLC7A5 (0.58) | SLC7A5OPRD1OPRM1YARS1MME | |
| SCHEMBL8529222 | 1.00 | SLC7A5 (0.58) | SLC7A5OPRD1OPRM1YARS1MME | |
| SCHEMBL8529219 | 1.00 | SLC7A5 (0.58) | SLC7A5OPRD1OPRM1YARS1MME | |
| SCHEMBL30520377 | 0.95 | OPRD1 (0.55) | SLC7A5OPRD1OPRM1YARS1MME | |
| SCHEMBL30017206 | 0.92 | OPRD1 (0.62) | SLC7A5OPRD1OPRM1YARS1MME | |
| SCHEMBL30839485 | 0.92 | OPRD1 (0.64) | SLC7A5OPRD1OPRM1YARS1OPRK1 | |
| SCHEMBL31193449 | 0.92 | OPRD1 (0.52) | SLC7A5OPRD1OPRM1YARS1MME | |
| SCHEMBL30839484 | 0.92 | OPRD1 (0.64) | SLC7A5OPRD1OPRM1YARS1OPRK1 | |
| SCHEMBL29823718 | 0.91 | OPRD1 (0.70) | OPRD1OPRM1MMEOPRK1 | |
| SCHEMBL22872688 | 0.90 | ERAP2 (0.52) | SLC7A5OPRD1OPRM1YARS1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240350577-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING DOMINANT OPTIC ATROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-10-24 | — | — | US | disclosed |
| US-11612633-B2 | Methods and compositions for preventing or treating ophthalmic conditions | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240350577-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING DOMINANT OPTIC ATROPHY | CRYAA, CRYAB, PRPH | SLC7A5 758/4885OPRD1 4259/4885OPRM1 4204/4885 |
| US-11612633-B2 | Methods and compositions for preventing or treating ophthalmic conditions | CRYAA, CRYAB, IAPP | SLC7A5 1710/4885OPRD1 4105/4885OPRM1 4245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.